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Recurrent mutations in the spliceosome are
observed in several human cancers, but their func-
tional and therapeutic significance remains elusive.
SF3B1, the most frequently mutated component of
the spliceosome in cancer, is involved in the recogni-
tion of the branch point sequence (BPS) during selec-
tion of the 30 splice site (ss) in RNA splicing. Here, we
report that common and tumor-specific splicing
aberrations are induced by SF3B1 mutations and
establish aberrant 30 ss selection as the most
frequent splicing defect. Strikingly, mutant SF3B1
utilizes a BPS that differs from that used by wild-
type SF3B1 and requires the canonical 30 ss to enable
aberrant splicing during the second step. Approxi-
mately 50% of the aberrantly spliced mRNAs are
subjected to nonsense-mediated decay resulting in
downregulation of gene and protein expression.
These findings ascribe functional significance to the
consequences of SF3B1 mutations in cancer.INTRODUCTION
RNA splicing, a highly regulatedmolecular event orchestrated by
the spliceosome, involves the removal of intronic sequences
from pre-mRNA and the ligation of exons to generate mature
mRNA (Matera and Wang, 2014; Wahl et al., 2009). This process
can result in multiple mRNAs being produced from a single gene
providing increased protein diversity in cells. Dysregulation of
RNA splicing has been identified as a causative defect in several
diseases (Dehm, 2013; Singh and Cooper, 2012). Furthermore,
dysregulated alternative splicing has been proposed to play anCell Reimportant role in tumorigenesis and resistance to therapy; how-
ever, in many cases, the molecular consequences of dysregu-
lated splicing in cancer have remained largely elusive (Zhang
and Manley, 2013). Recently, recurrent heterozygous mutations
were identified in components of the spliceosome in various tu-
mor types suggesting that somatic mutations in spliceosome
genes play an important role in cancer (Yoshida and Ogawa,
2014). SF3B1 is the most frequently mutated spliceosome
gene with particular enrichment in diseases such as myelodys-
plastic syndromes (MDS), chronic lymphocytic leukemia (CLL),
chronic myelomonocytic leukemia, uveal melanoma (UVM),
skin melanoma (SKCM), and breast (BRCA) and pancreatic can-
cers (Biankin et al., 2012; Ellis et al., 2012; Harbour et al., 2013;
Kong et al., 2014; Landau et al., 2013; Malcovati et al., 2015;
Yoshida et al., 2011). Based on the high frequency of SF3B1mu-
tations and the key role in splicing of this protein, we sought to
study the molecular and functional consequences of SF3B1 hot-
spot mutations on RNA splicing in cell lines and patient samples.
Splicing takes place after the recognition of consensus se-
quences near the 50 and 30 ends of introns, known as 50 and 30
splice sites (ss), by the splicingmachinery. U1 small nuclear ribo-
nucleoprotein particle (snRNP) recognizes the 50 ss, whereas U2
snRNP is directed to the appropriate 30 ss by short, conserved
pre-mRNA sequences, including a branch point sequence
(BPS), the polypyrimidine (Py) tract, and the AG dinucleotide at
the intron-exon junction. Prior to U2 snRNP recruitment, SF1
recognizes the BPS, the U2 auxiliary factor (U2AF) large subunit
(U2AF2) recognizes the Py tract, and U2AF small subunit
(U2AF1) recognizes the AG dinucleotide. Subsequently, the U2
snRNP replaces SF1 in an ATP-dependent process that facili-
tates protein and RNA rearrangements. In particular, the N termi-
nus of SF3B1, a U2 snRNP component, has been shown to bind
with U2AF2, whereas the SF3B1 C terminus along with another
U2 snRNP component, p14, interacts with the BPS and nearby
pre-mRNA sequences (Gozani et al., 1998). In addition, U2ports 13, 1033–1045, November 3, 2015 ª2015 The Authors 1033
snRNP and pre-mRNA complex is stabilized by a base-paired
duplex between the U2 snRNA and the BPS. The subsequent
binding of U4/U5/U6 tri-snRNP induces structural rearrange-
ments that lead to activation of two catalytic steps that generate
the lariat intermediate and subsequent final exon-exon product
(Horowitz, 2012; Matera and Wang, 2014; Wahl et al., 2009).
The recurrent hotspot mutations in SF3B1 are found exclu-
sively in the C-terminal HEAT domains (residues 622–781; Fig-
ure S1A). Though there has been lack of structural information
on how SF3B1 interacts with pre-mRNA, previous cryo-electron
microscopy studies suggest that SF3B1 may undergo a confor-
mational change to a more open form that enables mRNA bind-
ing and BPS recognition by the U2 snRNP (Golas et al., 2003).
Although it was previously reported by several groups that
SF3B1 mutant-positive cancers are associated with aberrant
splicing (DeBoever et al., 2015; Furney et al., 2013; Gentien
et al., 2014; Landau et al., 2013), here, we show that SF3B1 hot-
spot mutations (SF3B1MUT) result in neomorphic activity causing
aberrant splicing. Moreover, we provide experimental evidence
that SF3B1MUT induces aberrant 30 ss selection through the
use of a branch point (BP) different from the BP utilized by
SF3B1 wild-type (SF3B1WT) and that SF3B1MUT still requires
the canonical Py tract for the formation of the active spliceosome
to induce aberrant splicing. We predict that approximately half of
the aberrantly spliced mRNAs are subjected to nonsense-medi-
ated mRNA decay (NMD) (Kervestin and Jacobson, 2012).
Furthermore, we provide direct evidence that multiple aberrant
transcripts are degraded, resulting in downregulation of the
associated canonical protein in cell linemodels and patient sam-
ples. These insights into the splicing aberrations induced by
SF3B1MUT will enable discovery of downstream consequences
that contribute to neoplasms and the discovery of targeted ther-
apeutic approaches for SF3B1MUT cancers.
RESULTS
SF3B1MUT Tumor-Specific Splicing Defects
To provide a more complete understanding of the splicing
aberrations observed in SF3B1MUT cancers, RNA-sequencing
(RNA-seq) data from different tumor types were analyzed using
a bioinformatic pipeline that we developed in order to quantify
exon-exon junctions without the need of predetermined alterna-
tive splicing models or annotated splice junctions. The analysis
pipeline was applied to CLL patient samples (7 SF3B1MUT and
6 SF3B1WT) and a number of samples from the Cancer Genome
Atlas: luminal A primary BRCA (7 SF3B1K700E and 14 SF3B1WT),
SKCM (3 SF3B1MUT and 12 SF3B1WT), and UVM (18 SF3B1MUT
and 18 SF3B1WT) (Table S1). This analysis revealed 895 aberrant
splice junctions to be significantly upregulated in SF3B1MUT
compared to SF3B1WT of which 534 events (60%) were unique
as they had not been previously annotated in major transcrip-
tome databases. The majority of aberrant splicing events
observed were aberrant 30 ss selection (Figures 1A and S1B;
Table S2), consistent with previous observations (DeBoever
et al., 2015; Furney et al., 2013; Gentien et al., 2014; Landau
et al., 2013).
Unsupervised clustering was applied to the identified aberrant
junctions and it led to clustering of SF3B1MUT samples distinct1034 Cell Reports 13, 1033–1045, November 3, 2015 ª2015 The Autfrom the cluster of SF3B1WT samples (Figure 1B), with the excep-
tion of two SF3B1MUT samples (TCGA-D8-A1JH and TCGA-ER-
A19S) that clustered with the SF3B1WT samples. This was likely
driven by low mutant allele fractions (7% and 14%, respectively)
when compared with a range of 25%–52% for other samples
(Figure 1B; Table S2). Moreover, samples with SF3B1MUT clus-
tered within each tumor type (BRCA, SKCM, UVM, and CLL),
each showing a set of unique aberrantly spliced junctions (Fig-
ures 1B and S1C). A set of ‘‘common’’ events (i.e., events found
in all tumor types) were observed, consistent with a small overlap
of splicing abnormalities found in CLL and UVM described in two
previous reports (Furney et al., 2013). The pattern of tumor-spe-
cific splicing in BRCA and CLL could, at least in part, be ex-
plained by the increased expression of the genes that are aber-
rantly spliced in these tumor types compared to the other
diseases (p = 7.5022 3 1005 and p = 1.0078 3 1036, respec-
tively); however, the same was not observed for SKCM and
UVM (Figure 1C; Table S3). This suggests that additional mech-
anisms, such as tissue-specific splicing regulation, might
contribute to these patterns.
Using the aberrant junctions identified in the previous analysis,
we extended the clustering analysis to include 14 MDS RARS
samples (12 SF3B1MUT) and an additional 19 samples from
TCGA with miscellaneous SF3B1 mutations (Table S1). For the
MDS samples, relatively low sequencing depth and inclusion of
just two SF3B1WT samples precluded their use for the discovery
of MDS-specific aberrant junctions. While all SF3B1MUT MDS
patients and three BRCA patients (p.N626D, p.D781E, and
p.K666E) clustered with the original SF3B1MUT sample set, 16
SF3B1 mutant patients clustered with SF3B1WT samples (Fig-
ure S1D). These patient samples carried mutations in SF3B1
(‘‘Non-hotspot’’ in Figure S1D and Table S1) that are not co-
localized with the hotspot mutations in the HEAT domain. These
analyses strongly suggest a convergence of mechanism and
downstream splicing effects induced by SF3B1MUT.
SF3B1 Mutations Induce Aberrant mRNA Splicing in
Human and Mouse Cells
To study SF3B1MUT in vitro, a pancreatic cancer cell line carrying
endogenous SF3B1 mutations (Panc05.04: p.Q699H and
p.K700E) was utilized. In addition, the p.K700E, p.K666N, or
p.H662Q mutation (Nalm-6 SF3B1K700E, Nalm-6 SF3B1K666N,
Nalm-6 SF3B1H662Q) or a synonymous mutation (Nalm-6
SF3B1K700K, referred as SF3B1WT) was introduced by AAV-
mediated homology to the Nalm-6 pre-B cell line to produce
isogenic matched cell lines. Unsupervised clustering of these
cell lines and a panel of several SF3B1WT pancreatic cancer
cell lines using the aberrant splice junctions identified in patient
samples resulted in clear segregation of SF3B1MUT cell lines
from SF3B1WT cells (Figure 2A). A similar increase in aberrant
splice junctions observed in RNA-seq data analysis was
confirmed in Panc05.04 and Nalm-6 SF3B1K700E cells using a
Nanostring assay developed to quantify aberrant splice junc-
tions (Figure S2A). Panc05.04 cells carry the hotspot mutation
p.K700E and a mutation at position 699 (p.Q699H) that is not
observed in patient samples. When the p.Q699H and p.K700E
were expressed alone or in combination in 293FT cells, only cells
expressing p.K700E and p.Q699H/p.K700E induced aberranthors
Figure 1. SF3B1MUT Are Associated with Abnormal Splicing
(A) Distribution of unique (orange) or known (violet) differential splicing events from each category across the four tumor types examined.
(B) Heatmap of SF3B1MUT-induced splicing alterations in patients: rows are splice junctions and columns are patients. Heatmap matrix values indicate percent
usage of the differential splice junction versus all other junctions sharing the same splice site, normalized as Z scores across patients and limited to amaximum of
jZj = 2. SF3B1 status information can be found in Table S1.
(C) Gene expression for each significantly abnormally and common spliced gene across the four different diseases, quantified in unit of TPM (transcripts per
million); * indicates the statistically significant diseases.
Box plots and whiskers are represented as per the Tukey method. See also Figure S1 and Tables S2 and S3.splicing indicating that p.Q699H does not appear to affect this
aberrant 30 ss selection (Figures S2B and S2C). These data
confirm that Panc05.04 and Nalm-6 SF3B1MUT cell lines are
representative models to study the splicing functional activity
of SF3B1MUT in vitro.
To confirm that additional cancer-associated SF3B1 hotspot
mutations induced aberrant splicing, we expressed various
mxSF3B1MUT, mxSF3B1WT or mxSF3B1K700R in 293FT cells
(see the Supplemental Experimental Procedures for a descrip-Cell Retion of mxSF3B1; Figure S2D) and analyzed splicing aberrations
by Nanostring. The p.K700R mutation served as a negative
control as it doesn’t introduce a major change in charge or
size of the amino acid and is not disease associated. All
SF3B1MUT tested demonstrated the same usage of aberrant
splice sites observed in endogenous and engineered cell lines;
however, the SF3B1K700R or SF3B1WT did not show these
splicing changes (Figure 2B). Moreover, the expression of any
of the SF3B1 constructs did not change the overall expressionports 13, 1033–1045, November 3, 2015 ª2015 The Authors 1035
Figure 2. Aberrant Splice Variants Are Associated with SF3B1MUT in Cell Lines
(A) Heatmap of SF3B1MUT-induced aberrant splicing in Nalm-6 isogenic cell lines with p.H662Q, p.K666N, and p.K700E as well as a panel of wild-type andmutant
pancreatic cell lines (row identities, orders, and annotations are the same as for patients in Figure 1B).
(B–D) Overall gene (PAN - gene), or abnormal (aberrant isoform) splice isoform expression quantified by Nanostring assay in (B) 293FT cells expressing SF3B1WT,
SF3B1K700R, or several SF3B1MUT and shRNA knockdown of SF3B1 wild-type or mutant allele or both in (C) Panc05.04 (SF3B1MUT) or (D) Panc10.05 (SF3B1WT).
Data are represented as mean of three biological replicates.
Data are presented in box plots as boxes in the first and third quartiles, midline as the median, and whiskers extending to the range excluding outliers. See also
Figure S2.(sum of aberrant and canonical) of affected genes (Figure 2B).
To further confirm the correlation between expression of
SF3B1 p.K700E mutation and aberrant splicing, tetracycline-
inducible short hairpin RNA (shRNA) was used to selectively
knockdown (KD) the SF3B1MUT or SF3B1WT allele in
Panc05.04 and Panc10.05 (SF3B1MUT and SF3B1WT cells). Af-
ter confirmation of KD efficiency (Figures S2E–S2H), RNA iso-
lated from treated cells was analyzed by Nanostring. Depletion
of the SF3B1MUT allele in Panc05.04 resulted in downregulation
of aberrant splice isoforms, whereas an accumulation of aber-
rant splice isoforms was observed with selective SF3B1WT1036 Cell Reports 13, 1033–1045, November 3, 2015 ª2015 The Autallele depletion (Figures 2C and 2D), indicating that SF3B1MUT
was responsible for the appearance of aberrant splicing. These
results were also supported by the expression of a pan shRNA
or depletion of SF3B1WT in the Panc10.05 where no effect on
aberrant splicing was observed (Figures 2C and 2D). Collec-
tively, these results strongly suggest that SF3B1MUT acquires
a neomorphic function and may also lose wild-type splicing ac-
tivity. This observation was also supported by the recent paper
by Zhou et al. proposing that in a different SF3B1 mutant cell
line (ESS1) wild-type SF3B1 was required for survival (Zhou
et al., 2015).hors
Figure 3. Aberrant AG Is Associated with a
Short and Weak Py Tract
(A) Density plot of the relative positions of cryptic
AGs compared to their canonical splice sites in
SF3B1MUT tissue cohorts. The distance to the first
AG (non-GAG trimer) from all RefSeq canonical
30 ss is included for comparison.
(B) Motif frequency plots for canonical, aberrant,
and first non-GAG AGs for 30 ss. The motifs are
given 35 nt upstream of the 30 AG and 3 nt
downstream. See also Figure S3.
(C) Sequences of different minigenes with specific
mutations highlighted in bold. The cryptic and
canonical AGs are underlined.
(D)Co-transfectionof variousZDHHC16minigenes
with mxSF3B1WT and mxSF3B1K700E (top gel) or
mxSF3B1K700R (bottom gel) cDNA in 293FT cells.
Shown here is a representative ethidium-bromide-
stained 2.5%agarose gel of the indicated RT-PCR
reactions of mRNA isolated from transfected cells.
See also Figures S4 and S5 and Table S4.SF3B1MUT Recognizes a Cryptic 30 AG with a Short and
Weak Py Tract
The most common splicing abnormality observed in SF3B1MUT
cells was the usage of an aberrant 30 ss. To understand the
sequence features and the mechanism by which mutant
SF3B1 would induce aberrant splicing, computational analysis
of SF3B1MUT patient data and minigene assay validation
methods were utilized. First, an enrichment of the cryptic AGs
was determined to be located between 15 and 24 nt up-
stream of the canonical 30 ss in SF3B1MUT patient samples (Fig-
ure 3A). In contrast, the first AG (but not GAG) upstream of a
canonical AG in RefSeq showed a much lower density in this re-
gion and a wider distribution. Interestingly, the motif sequences
associated with the cryptic and canonical AGs showed several
different features. Upstreamof the canonical AGs, a clear enrich-
ment of pyrimidines was observed in agreement with the pres-
ence of a Py tract, whereas the cryptic AGs were associated
with a short and weak Py tract and an enrichment of adenines
(A) that are possibly important for BPS selection. In contrast,
no clear features were associated with the first upstream AGsCell Reports 13, 1033–1045, Nin RefSeq (Figures 3B and S3). Interest-
ingly, similar features, such as the posi-
tion of cryptic AG between 15 and
24, the presence of a short and weak
Py tract, and an enrichment of As were
observed in aberrant 30 spliced junctions
detected in NIH 3T3 mouse cells
overexpressing mxSF3B1K700E (Figures
S4A–S4C). While similar features associ-
ated with aberrant splice junction usage
were observed in mxSF3B1K700E mouse
cells, the overlap of affected junctions
observed in human cells was low due to
low sequence similarity of introns be-
tween species (Figure S4D; Table S4).
An exception was observed for theUXS1 gene for which the junction between exon 2 and exon 3
is conserved among different species (Figure S4E). These data
strongly suggest that SF3B1MUT induces aberrant splicing in
the presence of competing 30 ss via a sequence-dependent
feature located within the intron and preferentially recognizes
cryptic splice sites with weaker Py tract in close proximity to
an enrichment of As.
To confirm the importance of these specific sequence fea-
tures, we selected the exon 9/exon 10 junction in ZDHHC16 to
develop a minigene as it was observed to be aberrantly spliced
among all the SF3B1 hotspot mutant samples analyzed. In addi-
tion, several alterations in the cryptic 30 ss, the length/strength of
the Py tracts, and the potential BPS were tested (Figure S5A).
Splicing was assessed by RT-PCR using cDNA prepared from
293FT cells co-transfected with ZDHHC16 minigene and
mxSF3B1 plasmid. As expected, when the ZDHHC16 exon 9,
intron 9 and exon 10 (E9-I9-E10) minigene was co-transfected
with mxSF3B1WT or mxSF3B1K700R, only canonical splicing
was observed, whereas in cells expressing mxSF3B1K700E and
all the other hotspot mutations, both canonical and aberrantovember 3, 2015 ª2015 The Authors 1037
splicing was detected (Figures 3C and 3D, lanes 4 and 5; Fig-
ure S5B). Interestingly, once the cryptic AG was removed
(E9-I9NoAG-E10), aberrant splicing was not observed even in
cells expressing mxSF3B1K700E (Figures 3C and 3D, lanes 6
and 7), indicating that the cryptic AG is necessary for aberrant
splicing. To understand whether exonic sequences play a role
in aberrant splicing, we looked at the preceding junction in
ZDHHC16 (E8-I8-E9). As expected, no aberrant splicing was
observed when this minigene was co-transfected with any of
the mxSF3B1 constructs (Figure 3D, lanes 10 and 11). Canonical
and aberrant splicing was detected when intron 8 between exon
8 and 9 was replaced with intron 9 (E8-I9-E9) in the
ZDHHC16 minigene and co-transfected with mxSF3B1K700E,
but not when co-transfected with mxSF3B1WT or mxSF3B1K700R
(Figure 3D, lanes 12 and 13). These results agree with the
computational analysis suggesting that the cryptic AG is neces-
sary and the intronic features are sufficient to induce aberrant
splicing by SF3B1MUT.
Identification of the 30 ss occurs during early assembly of the
spliceosome, in particular when the U2AF2/U2AF1 complex rec-
ognizes the Py tract and AG, and then again when the AG is
recognized during the second step of splicing (Horowitz, 2012).
To understand if the short and weak Py tract upstream of the
cryptic AG is sufficient to recruit the U2AF2/U2AF1 complex,
the length/strength of the canonical Py tract was reduced from
19 nt to 10, 6, and 2 nt (PyT 10n, PyT 6n, and PyT 2n, respec-
tively) or the weak and short cryptic Py tract was replaced with
a strong Py tract (SELEX) (Figure S5A) (Lim et al., 2011). When
the minigene PyT 2n (or PyT 10n and PyT 6n, in Figure S5C)
was co-transfected with the mxSF3B1WT or mxSF3B1K700R,
the splicing event occurred with selection of a new cryptic 30
ss within exon 10 positioned 54 nt downstream of the canonical
30 ss (sequencing data not shown), suggesting that the PyT 2n
was not recognized by U2AF complex (Figures 3C and 3D, lanes
14 and 15; Figure S5C). This is in agreement with previous re-
ports suggesting that Py tract length and strength are necessary
for the recruitment of U2AF2/U2AF1 to guide splicing to occur at
that position (Coolidge et al., 1997). Surprisingly, when the same
minigenes were co-transfected with mxSF3B1K700E, similar re-
sults were observed and splicing occurred within exon 10 at
the new cryptic 30 ss (Figures 3C and 3D, lanes 14 and 15), sug-
gesting that the short and weak Py tract upstream of the cryptic
AG is not sufficient to recruit the U2AF complex and that the
cryptic AG requires the downstream canonical Py tract to induce
aberrant splicing. The nucleotide base upstream of the AG
dinucleotide has been reported to be critical for U2AF1
interaction in early recognition of 30 ss and is usually a T/C in
consensus sequences (Ilagan et al., 2015). Hence, introduction
of a G upstream of the canonical or cryptic AG (3 T > G or
24 C > G) would potentially abolish their use as a 30 ss, respec-
tively. When 3 T > G minigene was co-transfected with either
mxSF3B1WT or mxSF3B1K700E constructs, splicing was
observed within exon 10, similar to PyT 2n, suggesting again
that the U2AF2/U2AF1 complex needs to be recruited at the ca-
nonical AG during first step of splicing to allow usage of the
cryptic AG by SF3B1MUT (Figures 3C and 3D, lanes 16 and 17).
Interestingly, when 24 C > G minigene was used, only canoni-
cal splicing was observed, even after mxSF3B1K700E expression1038 Cell Reports 13, 1033–1045, November 3, 2015 ª2015 The Aut(Figures 3C and 3D, lanes 8 and 9). These data suggest that
the 3 position relative to cryptic AG is also important when
the cryptic 30 ss is recognized during the second transesterifica-
tion reaction of splicing. Moreover, when the short and weak
cryptic Py tract was replaced with a SELEX Py tract, the cryptic
AG was used as the preferred 30 ss by cells expressing both
mxSF3B1WT or mxSF3B1K700E (Figures 3C and 3D, lanes 18
and 19). Taken together, these data support the notion that the
sequence features required by SF3B1MUT-containing U2 snRNP
complex are located within the intron and that the cryptic AG and
the downstream canonical Py tract are required to induce aber-
rant splicing by SF3B1MUT.
SF3B1MUT Utilizes a Different BPS
The computational analysis of motifs near the 30 ss showed an
enrichment of As upstream of the cryptic AG in human and
mouse mutant SF3B1 cells, suggesting the importance of this
sequence for the SF3B1MUT-incorporated U2 complex. DeBo-
ever and colleagues suggested that these were the BPSs for
the mutant and wild-type SF3B1 complexes using a BPS predic-
tion algorithm (DeBoever et al., 2015). Instead, we used the
recently mapped BPS data using K562 SF3B1WT cells and over-
laid these data with introns in which the aberrant splice junctions
were observed in SF3B1MUT cells (Mercer et al., 2015). A total of
151 BPs were mapped among 93 introns; 60 introns have only
one identified BP, and another 33 introns contain multiple re-
ported BPs. The distribution of these BPs with respect to the
cryptic AG indicated that the majority of BPs overlapped with
the A of the cryptic AG or were in close proximity (between 1,
cryptic A and 5), but did not coincide with the enrichment of
As observed in the motif analysis (Figure 4A). The enrichment
of As was observed between 8 and 18 nt upstream of the
cryptic AG in human and mouse cells expressing mutant
SF3B1 (Figures 4B and S4C). This suggests that these As could
play an important role for SF3B1MUT function. To test this hy-
pothesis, the 3 As located between 33 and 35 were mutated
to Gs in the ZDHHC16 minigene (33 to 35 AAA > GGG; Fig-
ure 4C and S5A). When this minigene was co-transfected with
mxSF3B1WT and mxSF3B1K700R, canonical splicing was
observed, suggesting that these As are not part of the BPS for
wild-type U2 complex (Figure 4D, lanes 11 and 12). Instead,
when the cells were co-transfected with mxSF3B1K700E, canon-
ical splicing was observed without any aberrant splicing, indi-
cating that the three As are probably part of the BPS used by
the U2 mutant complex (Figure 4D, lane 12). To identify the
BPS used by the U2 wild-type complex, the A at position 26
and 30 alone or together were mutated to G (26 A > G, 30
A > G and26,30 AA > GG; Figure 4C). When the A at position
26 alone or both26 and30weremutated toG and co-trans-
fected with mxSF3B1WT or mxSF3B1K700R, splicing was
observedwithin exon 10 at the new cryptic 30 ss (Figure 4D, lanes
5, 6 and 9, 10), suggesting that this is likely the BPS for SF3B1WT,
but not for SF3B1K700E, as canonical and aberrant splicing was
observed in these conditions (Figure 4D, lanes 5, 6 and 9, 10).
Interestingly, when the minigene with the A at position30 alone
was mutated to G (Figure 4C and S5A) and co-transfected with
mxSF3B1WT or mxSF3B1K700R splicing was observed mostly
within exon 10 and when co-transfected with mxSF3B1K700E,hors
Figure 4. SF3B1MUT Uses a Different BPS than SF3B1WT
(A) Relative positions ofmappedBP (n = 151) fromMercer et al. compared to the location of cryptic AGs identified in Nalm-6 SF3B1K700E cells (Mercer et al., 2015).
The x axis is given as the distance in nucleotides (nt) of the BP to the cryptic AG (upstream positions are negative distances), whereas the y axis is the frequency of
BP found at that position.
(B) The number of adenines found 8 to 18 nt upstream of cryptic AG compared to their canonical 30 ss are significantly different (***p = 5.89123 1029). Box plots
and whiskers are represented as per the Tukey method.
(C) Sequences of different minigenes with specific mutations highlighted in bold. The cryptic and canonical AGs are underlined.
(D) Co-transfection of various ZDHHC16 minigenes with mxSF3B1WT and mxSF3B1K700E (top gel) or mxSF3B1K700R (bottom gel) cDNA in 293FT cells. Shown
here is a representative ethidium-bromide-stained 2.5% agarose gel of the indicated RT-PCR reactions of mRNA isolated from transfected cells.
(E) Endogenous ZDHHC16 intron 9 lariat sequencing analysis using nested PCR products of isolated RNA from K562 SF3B1K700E or SF3B1WT isogenic cells. See
also Figure S5 and Table S5.
Cell Reports 13, 1033–1045, November 3, 2015 ª2015 The Authors 1039
Figure 5. 44% of All Aberrantly Spliced
Genes Are Putative Targets of NMD
(A) Frequency of cryptic AGs identified in Nalm-6
SF3B1K700E cells at each indicated position. Posi-
tions corresponding to a multiple of 3 are shown in
red. The x axis is given as the distance in nt from
the cryptic to the canonical AG, whereas the y axis
is the frequency of AG found at that position.
(B) Diagram of the ‘‘NMD rule.’’ Premature termi-
nation codons (PTCs) found more than 55 nt from
the last exon-exon junction induce mRNA degra-
dation by NMD (Rivas et al., 2015).
(C) Comparison of whole gene expression of pre-
dicted NMD-sensitive (n = 224) and NMD-insen-
sitive (n = 286) transcripts given as the log2 fold
change between Nalm-6 SF3B1K700E and
SF3B1WT cells. NMD predictions were derived
from aberrant junctions identified in Nalm-6
SF3B1K700E isogenic cells.
(D) Log2 fold changes of genes selected from (B)
whichexhibit downregulation inNalm-6SF3B1K700E
cells (DMSO) and rescue effect upon treatment for
1 hr with cycloheximide (+CHX) (n = 41).
Box plots and whiskers are represented as per the
Tukey method. See also Figure S7 and Tables S6
and S7.only aberrant splicing was observed (Figure 4D, lanes 7 and 8).
As expected, when all the As were mutated to Gs (all A > G, Fig-
ures 4C and S5A), each mxSF3B1 construct spliced within exon
10 (Figure 4D, lanes 13 and 14). Additionally, this outcome was
confirmed by mapping the two different BPs using nested PCR
analysis and sequencing of endogenous ZDHHC16 intron 9 lariat
in K562 isogenic cells (Figure 4E). Unlike in SF3B1WT cells, we
observed at least two major templates with different sequences
in the SF3B1K700E cells due to a mixed population of SF3B1WT
and SF3B1MUT proteins. Through analysis and matching of ex-
pected transcript sequences using Mutation Surveyor, we found
that 34 A and 30 A were the BPs used for SF3B1K700E and
SF3B1WT, respectively. To extend our observation, we also
mapped BPs in four additional genes that are aberrantly spliced
in presence of SF3B1K700E: TMEM14C (intron 1), SEPT6
(intron 9),DLST (intron 5), andDIP2A (intron 23) (Table S5). These
results prove that the SF3B1 wild-type and mutant-containing
U2 complexes are able to use two different BPs.
Aberrant Transcripts Generated by SF3B1MUT Are
Subjected to NMD
Erroneous or aberrant mRNAs that contain a premature termi-
nation codon are subjected to NMD to prevent potential delete-
rious effects of their translation to proteins (Kervestin and
Jacobson, 2012). Computational analysis revealed that the ma-
jority of cryptic AGs were located upstream of canonical 30 ss
at nucleotide distances that were not multiples of 3 (Figure 5A).
This result suggested that the aberrant transcripts would have a
higher probability to be out of frame and therefore degraded by
NMD. To confirm that predicted NMD-sensitive transcripts1040 Cell Reports 13, 1033–1045, November 3, 2015 ª2015 The Autwere degraded by the NMD pathway, RNA-seq was performed
on Nalm-6 SF3B1K700E cells treated with cycloheximide, a
translation inhibitor known to inhibit NMD (Singh et al., 2012).
Bioinformatic prediction analysis revealed that 44% of all aber-
rant mRNAs identified in Nalm-6 SF3B1K700E cell lines would
result in an NMD-sensitive transcript (Rivas et al., 2015) (Fig-
ure 5B; Tables S6 and S7). RNA-seq analysis from Nalm-6
isogenic cells demonstrated that NMD-sensitive genes were
expressed at significantly lower levels in Nalm-6 SF3B1K700E
than Nalm-6 SF3B1WT (p = 1.06 3 1012), whereas predicted
NMD-insensitive genes were expressed at similar levels (Fig-
ure 5C). RNA-seq analysis identified 41 predicted NMD-sensi-
tive genes to be both downregulated in Nalm-6 SF3B1K700E
and to have increased abundance following cycloheximide
treatment (Figure 5D; Table S6), suggesting that these aberrant
transcripts were degraded by the NMD. In addition, to evaluate
if this would result in downregulation of the associated canon-
ical protein, stable isotope labeling of amino acids in culture
(SILAC) with subsequent mass spectrometry was used to
quantify protein levels in Nalm-6 isogenic lines (Oda et al.,
1999)$ Eleven predicted NMD-sensitive transcripts for which
peptides could be detected in Nalm-6 SF3B1WT were selected
for evaluation, and ten were found to have decreased peptide
counts by at least 2- to 8-fold (e.g., ABCB7, AKAP8L; Fig-
ure 6A). Decreased expression of canonical proteins was
confirmed by western blot analysis using available antibodies,
such as MZB1, PHGDH, and SEPT6 (Figure 6B). Among the
downregulated proteins in the SILAC experiment were two pro-
teins of particular interest: MZB1 and ABCB7. MZB1 is a B cell-
specific and ER-localized protein implicated in antibodyhors
Figure 6. MZB1 and ABCB7 Canonical Iso-
form mRNA and Protein Are Downregulated
in SF3B1 Mutant Nalm-6 Cells and Patients
(A) Log2 peptide counts matching selected NMD
target proteins in Nalm-6 isogenic cells relative to
counts in Nalm-6 SF3B1WT cells.
(B) Western blots of selected NMD target proteins
in parental, SF3B1WT and SF3B1K700E Nalm-6
cells.
(C) Sequence fragment density from four RNA-seq
experiments, two each from Nalm-6 SF3B1WT and
SF3B1K700E. The aberrant 30 ss leads to introduc-
tion of a PTC in exon 3 (not shown).
(D) MZB1 and ABCB7 canonical isoform mRNA
is reduced relative to SF3B1WT in Nalm-6
SF3B1K700E cells asmeasured by qPCR. Error bars
represent SD between biological replicates.
(E) MZB1 western blots from 10 CLL patient sam-
ples: patients 1–5 are SF3B1WT; patients 6, 7, and
9 are SF3B1K700E; patient 8 is SF3B1Y623C; and
patient 10 is SF3B1E622D.
(F) Sequence fragment density from four RNA-seq
experiments, two each from Nalm-6 SF3B1WT and
SF3B1K700E. An aberrant 30 ss between exon 8 and
9 of ABCB7 causes the addition of a PTC in a 7 AA
addition to the protein sequence (in gray) prior to
the start of the next canonical exon (in blue).
See also Figure S6.secretion and integrin-mediated cell adhesion (van Anken et al.,
2009). As shown in Figure 6C, MZB1 was aberrantly spliced in
SF3B1K700E cells and the canonical isoform was clearly down-
regulated at transcript and protein level (Figures 6A, 6B, and
6D). As shown in Figure 6E, clear downregulation of canonical
MZB1 protein level was also observed in four out of five CLL
patients with SF3B1MUT, but not in SF3B1WT samples. The
result for patient 8 could be explained by the low allele fraction
for Y623C (10%), and this was associated with undetectable
aberrant splicing for ZDHHC16 and no change in canonical
MZB1 when compared with one of the SF3B1WT patients (Fig-
ure S6). ABCB7 is a mediator of iron accumulation and
erythroid growth and has been reported to be downregulated
specifically in an MDS subtype characterized by refractory ane-
mia with ringed sideroblasts (RARS) (Boultwood et al., 2008).
Interestingly, SF3B1 mutations have been found at a frequency
of 80%–90% in RARS, but not in other MDS subtypesCell Reports 13, 1033–1045, N(Papaemmanuil et al., 2011). In addition,
a partial loss-of-function mutation in
ABCB7 has been identified in X-linked
sideroblastic anemia and ataxia demon-
strating an iron-overload phenotype in
cells with defective ABCB7 (Allikmets
et al., 1999). We identified that ABCB7
is aberrantly spliced in SF3B1 mutant
cells (Figure 6F) and demonstrated that
the aberrant transcript is subject to
NMD, causing downregulation of the ca-
nonical transcript and protein (Figures 6A
and 6D). Therefore, aberrant splicing andsubsequent NMD of ABCB7 likely explains the association be-
tween ABCB7 downregulation observed in RARS and the pres-
ence of SF3B1 mutants. Taken together, these data suggest
that SF3B1MUT might contribute to the phenotypes observed
in diseases by inducing the generation of NMD-sensitive tran-
scripts through aberrant splicing and to a subsequent reduction
in the levels of the corresponding proteins.
DISCUSSION
In the current study, we describe the mechanism by which
SF3B1 hotspot mutations induce aberrant splicing and the fate
of resulting NMD-sensitive aberrant mRNAs in several cancer
types. These mutations are associated with the expression of
hundreds of aberrantly spliced junctions, mostly by utilizing a
cryptic AG. While some aberrant junctions are common across
different cancer types, others are tumor specific, which inovember 3, 2015 ª2015 The Authors 1041
Figure 7. Model for SF3B1MUT Function dur-
ing Cryptic 30 ss Selection
(A) Surface electrostatic potential map of SF3B1WT
generated based on its homology model with the
crystal structure of importin-b (PDB: 1UKL). The
color scheme of the electric potential surface
is +10 V (blue) and 10 V (red). The position of the
hotspot mutations located in the five HEAT repeat
domains (highlighted in yellow) is represented in
the inset.
(B and C) Schematic representation of splicing in
SF3B1WT (B) and SF3B1MUT (C) cells and molec-
ular consequences of transcripts is also shown.some cases is a consequence of tissue-specific gene expres-
sion; however, additional factors likely contribute to these differ-
ences. Interestingly, aberrant splicing was observed only in
patients carrying hotspot mutations located in the C-terminal
HEAT domains, but not in samples from ‘‘non-hotspot’’ patients,
as they clustered with the SF3B1WT patients in aberrant junction
usage comparisons. The majority of these non-hotspot muta-
tions are located away from the HEAT repeat domains, which
suggests that they may have different effects on cancer cells
or simply are passenger mutations, and are not the focus of
the present study. We calculated an electrostatic potential
map based on a homology model of SF3B1WT with importin-b
and observed that all hotspot mutations are co-localized in a
limited, positively charged region even though they are distrib-
uted across five different HEAT domains (Figure 7A). Further-
more, while there are various amino acid substitutions at the
hotspots that result in change of size and/or polarity of side
chains, our data suggest the functional consequences on
splicing for these changes are similar. We show that hotspot
SF3B1MUT induces aberrant 30 splicing in junctions associated
with specific sequence features: an enrichment of As followed
by a short and weak Py tract upstream of the cryptic AG located
15 to 24 nt from the canonical 30 ss.
Based on computational analysis, it was recently suggested
that SF3B1 mutations cause a change in the size of the sterically
protected region downstream of the BP without any altered BP
recognition allowing the utilization of the cryptic AG (DeBoever
et al., 2015). It was also suggested that SF3B1 mutations could
alter interactions with U2AF2, affecting the ability to recognize
the canonical 30 ss and leading to cryptic 30 ss selection. In
contrast, we provide experimental evidence that the short and1042 Cell Reports 13, 1033–1045, November 3, 2015 ª2015 The Authorsweak Py tract upstream of the cryptic
AG is insufficient for the recruitment of
the U2AF complex and that the integrity
of the canonical 30 ss, and thereby inter-
action with U2AF2 is required to observe
aberrant splicing as well. In addition, we
have demonstrated that the SF3B1MUT
U2 complex utilizes a BP that is different
from the one used by the wild-type U2
complex (proposed model, Figures 7B
and 7C). Based on these data and the
restricted localization of the hotspot mu-tations, we hypothesize that SF3B1MUT interacts differently
with the pre-mRNA or splicing factors that are important for
the recognition of AG during the second step of splicing. The
close proximity of the two mapped BPs for ZDHHC16 (30A
for SF3B1WT and 34A for SF3B1MUT) reported here (Figure 4E)
and the published data on the crosslinking of SF3B1 to bases
flanking the BPS (Gozani et al., 1998) would suggest a competi-
tion between the SF3B1WT- and SF3B1MUT-incorporated U2
snRNP complexes to select the canonical or cryptic AG for
splicing, respectively. The mechanism by which SF3B1MUT fa-
vors selection of a different BP can only be speculated at this
point. Based on our data and a previous study investigating spli-
ceostatin A’smechanism of action (Corrionero et al., 2011), there
are at least two hypotheses: the selection of the new BP is
guided by SF3B1MUT through enhanced direct interactions with
specific nucleotides flanking the new BPS compensating for
reduced base pairing with U2 snRNA or by the base pairing of
U2 snRNA with the new/suboptimal BPS compensating for
impaired interactions of SF3B1MUT across the canonical BPS.
Although SF3B1MUT does not seem to affect the pre-assembly
of U2 snRNP (preliminary data not shown), it is possible that the
interactions with splicing factors involved in selection of an alter-
native AG in the second step of splicing are impaired. Previously,
it has been reported that the second step splicing factor, Slu7, is
required for correct 30 ss selection (Chua and Reed, 1999a,
1999b). Similar to U2AF1, Slu7 harbors a Zn knuckle domain,
and it is conceivable that it directly interacts with AG during the
second step of splicing. As observed in the case of SF3B1MUT,
depletion of Slu7 results in selection of a cryptic AG closer to
the BPS. This suggests that SF3B1 hotspot mutations may
impair the recruitment of Slu7 to the catalytic core. Additionally,
it has been reported that splicing factor SPF45 (hSPF45 is
RBM17) is involved in recognition and activation of an alternative
AG upstream of the canonical 30 ss. It has been suggested that
SPF45 directly or indirectly binds to the upstream alternative
AG with the help of SF3B1 and promotes its utilization during
the second catalytic step (Corsini et al., 2007; Lallena et al.,
2002). Interestingly, as observed in the present study for
SF3B1MUT, SPF45 also depends on the integrity of the canonical
30 ss to splice at the alternative AG. Since SF3B1MUT binds at a
different BPS, it can be speculated that the recruited SPF45
can access the cryptic AG which is otherwise prevented due to
the steric hindrance by SF3B1WT. Taken together, the SF3B1
hotspot mutations could be facilitating SPF45 activity and/or
abrogating Slu7 activity for selection of the aberrant AG, thereby
providing an unanticipated mechanism for regulation of splice
site utilization.
Alternative splicing of pre-mRNAs is a known cellular mecha-
nism that adds complexity and flexibility in gene expression to
induce stage-specific patterns not only by inducing expression
of a particular isoform but also by engaging NMD to downregu-
late gene expression (Ge and Porse, 2014; Kalyna et al., 2012).
Here, we predicted that approximately half of the aberrantly
spliced transcripts in SF3B1MUT cells are NMD sensitive, and
we have demonstrated that the associated canonical isoforms
are downregulated at the mRNA and protein levels. The down-
regulation of a large number of genes induced by this ‘‘spliceo-
some sickness’’ could be the cause of impaired cell functions
that contribute to cancer phenotypes and potentially create de-
pendency on essential genes or pathways for survival. Interest-
ingly, haploinsufficiency is a proposed mechanism for disease
pathogenesis in MDS, where chromosome 5q is deleted and
decreased expression of genes located on the remaining chro-
mosome is observed (e.g., RPS14 and CSKN1A1; Ebert et al.,
2008; Schneider et al., 2014). It is plausible that SF3B1 muta-
tions contribute to MDS in a similar fashion by downregulating
expression of certain genes resulting in a non-classical path
to haploinsufficiency. In addition to the downregulation of ca-
nonical proteins, it is also possible that NMD-insensitive aber-
rant transcripts are translated into aberrant proteins that have
altered function. Proteomic analysis of isogenic SF3B1MUT cells
did not reveal the presence of aberrant proteins (data not
shown), but this may be due to limitations of assay sensitivity,
and additional targeted SILAC or deep RNA sequencing of
active ribosome fractions may have the required sensitivity to
detect such proteins. Recently, several groups reported the mo-
lecular consequences and phenotypic effects of other spliceo-
some mutations, such as U2AF1 and the exonic splicing
enhancer binding serine/arginine-rich protein SRSF2 (Ilagan
et al., 2015; Kim et al., 2015; Shirai et al., 2015). Though there
are some overlaps in genes differentially spliced in tissues
affected by each spliceosome mutation, we see only minimal
overlaps in predicted NMD targets (Figure S7). However, muta-
tions in all three splicing factors are observed in MDS and are
mutually exclusive, suggesting that some of the downstream ef-
fects might be common. Thus, while not explored in this study, it
is likely that SF3B1 mutations result in defects in hematopoiesis,
as has been observed in animal models of SRSF2 and U2AF1
mutations. Additional work is ongoing to define the downstreamCell Resplicing abnormalities that drive the phenotypic effects of spli-
ceosome mutations. Finally, it is also plausible that mutations
in SF3B1 impact other proposed splicing regulators (e.g., chro-
matin, histone modifications), and these should be the subject
of future study (de Almeida et al., 2011; Kfir et al., 2015; Khan
et al., 2013).
In summary, computational and experimental approaches
were used to demonstrate that SF3B1MUT utilizes a different
BP to induce aberrant splicing across multiple cancer types.
These insights describe a neomorphic activity for SF3B1 muta-
tions that causes downregulation of canonical protein expres-
sion. Furthermore, these studies provide a foundation for the
potential discovery of targeted approaches for the treatment of
patients carrying SF3B1 hotspot mutations.EXPERIMENTAL PROCEDURES
For all RNA-seq data, reads were aligned to hg19 by STAR, gene isoform
counts were quantified by Sailfish against GENCODE annotation version
v19, and differential splice junctions were identified and measured as percent
spliced in (PSI). They were assessed between SF3B1MUT and SF3B1WT patient
samples from different cancer types and a panel of pancreatic and Nalm-6
isogenic cell lines usingmoderated t test defined in the Bioconductor’s limma
package. Pictograms of consensus sequences for motif and cross-species
analyses were generated using WebLogo. Hemagglutinin (HA)-tagged cDNAs
of SF3B1WT and SF3B1MUT generated by in vitro mutagenesis were trans-
fected into 293FT cells and isolated RNA was analyzed by Nanostring assay
to quantify canonical and aberrant splicing. Similarly, RNA isolated from
Panc05.04 and Panc10.05 infected with an inducible allele specific SF3B1
shRNA was analyzed by Nanostring. Knockdown and overexpression were
confirmed through qPCR and western blot analysis. ZDHHC16 minigenes
were designed and used in transient co-transfection with wild-type or mutant
mxSF3B1 in 293FT cells. Total RNA was extracted for RT-PCR and products
were resolved through gel electrophoresis to analyze the splicing pattern.
For lariat sequencing, K562 isogenic cells were used for total RNA extraction
and nested PCR analysis. Nalm-6 isogenic cell lines treated with DMSO or
cycloheximide were used for NMD analysis. NMD prediction was carried
based on the existence of PTCs found >55 nt upstream of the last exon-
exon junction in a transcript. For SILAC, Nalm-6 SF3B1WT and Nalm-6
SF3B1K700E cells were labeled with ‘‘light’’ 12C6,
14N4 L-arginine and
12C6,
14N2 L-lysine, or ‘‘heavy‘‘
13C6,
15N4 L-arginine and
13C6,
15N2 L-lysine-2HCl,
respectively. After liquid chromatography mass spectrometry analysis, pep-
tides were identified by automated database searching X!Tandem with the
SwissProt human database. RNA and proteins from CLL patient samples
were isolated to confirm downregulation of several transcripts and proteins
identified in the isogenic cell line SILAC experiment. MiSeq sequencing anal-
ysis was used to quantify allele frequency in patient samples. The SF3B1HEAT
repeats homology model (residue of 497–1,285) was generated by the
SWISS-MODEL web server based on the crystal structure of importin-b
(PDB: 1UKL). A complete description of themethods is provided in the Supple-
mental Experimental Procedures.ACCESSION NUMBERS
RNA-seq datasets have been deposited to theNCBI GEO and are available un-
der accession number GEO:GSE72790.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and seven tables and can be found with this article online at
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